Press Releases Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:54 2024-04-30 am EDT			5-day change	1st Jan Change
5,272 ^ILa	+6.87%		+7.92%	+38.19%

06:01pm	Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	MT
05:51pm	FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	04:01am	BU
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	Apr. 17	AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	Apr. 16	BU
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	Apr. 16	AQ
Teva Pharmaceutical Industries : Immediate Report	Apr. 16	PU
Teva Pharmaceutical Industries : Immediate Report	Apr. 16	PU
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	Apr. 16	BU
Teva enters into oncology biosimilar licensing agreement	Apr. 16	AQ
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	Apr. 11	BU
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	Apr. 09	BU
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY Extended-Release Injectable Suspension at SIRS 2024	Apr. 08	AQ
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	Apr. 06	BU
TEVA Successfully Opposed Trademark AZILIDE	Apr. 05	AQ
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate	Apr. 04	BU
Clinical Collaboration Agreement Established between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler Respiratory Program	Apr. 02	AQ
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement	Apr. 01	BU
TEVA UK AND CLOSED LOOP MEDICINE ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE DEVELOPMENT OF PERSONALISED MEDICINES	Mar. 27	AQ
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in China	Feb. 27	AQ
Alvotech and Teva Announce U.S. Approval of SIMLANDI injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira	Feb. 26	AQ
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China	Feb. 26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT